Becton Dickinson & Co. Q3 FY2026 Earnings Call Summary

BDX NYSE Healthcare 📅 2026-08-06 ⏱ ~60 sec read 🟢 Bullish

⏱️ 60-Second Brief Becton Dickinson & Co. · Q3 FY2026

Stock Next Day

▼ 0.28%

$177.07 → $176.57

Revenue

$5.0B

EPS

$12.62

AI Sentiment

🟢 Bullish

The company exceeded expectations on key financial metrics, …

📌 Bottom Line: BD reported a strong third quarter for fiscal 2026, with revenue of $5.0 billion and adjusted diluted EPS of $3.23, both exceeding expectations and demonstrating robust operational momentum. This solid performance led th…

🤖 AI-Assisted Summary — Produced using a custom AI pipeline by Abhi, reviewed for accuracy. · ⚠️ Not financial advice. For informational purposes only. Full Disclaimer →

✍️ EarningsBloom Editorial Team · 📅 Last updated: 2026-08-07 · 📎 Source: SEC EDGAR / Company Press Release

📋 TL;DR — What Happened

BD reported a strong third quarter for fiscal 2026, with revenue of $5.0 billion and adjusted diluted EPS of $3.23, both exceeding expectations and demonstrating robust operational momentum. This solid performance led the company to raise its full-year guidance, signaling confidence in its strategic direction and ability to deliver sustainable growth.

📊 Key Financial Metrics

Revenue $5.0B

EPS (Diluted) $12.62

AI Sentiment 🟢 Bullish The company exceeded expectations on key financial metrics, significantly improved cash flow, and raised its full-year guidance, indicating strong operational health and strategic execution.

✅ What Went Well

✅ Outperforming Financial Projections: BD significantly exceeded its internal expectations for the third quarter, delivering reported revenue of $5.0 billion, a 5.4% increase year-over-year, and adjusted diluted EPS of $3.23, up 4.9% from the prior year. This strong performance underscores effective operational management and market responsiveness.

✅ Exceptional Cash Flow Growth: The company demonstrated remarkable financial health through its cash generation, with year-to-date cash from continuing operations increasing by 33.3% to $2.1 billion and free cash flow expanding by an impressive 44.6% to $1.7 billion. This robust cash position provides flexibility for future investments and shareholder returns.

✅ Strategic Innovation and Market Expansion: BD continued to drive growth through innovation and key collaborations, exemplified by the launch of the Elyra™ Thulium Fiber Laser System to enhance kidney stone care and a partnership with EMS in Brazil to expand access to GLP-1 therapies using BD's Vystra™ Injection Pen platform. These initiatives highlight the company's commitment to advancing healthcare solutions and capturing new market opportunities.

⚠️ Concerns & Risks

⚠️ Global Macroeconomic and Geopolitical Volatility: The company acknowledged significant risks stemming from ongoing macroeconomic conditions, including inflationary pressures, currency and interest rate fluctuations, and global oil price volatility. Furthermore, geopolitical developments in regions such as Iran, the Middle East, Ukraine, and Asia pose potential threats to global transportation networks, supply chain stability, and overall operational costs.

⚠️ Evolving Regulatory Landscape and Competitive Pressures: BD faces challenges from changes in U.S. federal and state healthcare policies, the rapid evolution of medical technologies including artificial intelligence (AI), and shifts in reimbursement practices and third-party payer cost containment measures. The competitive environment, coupled with governmental initiatives like China’s volume-based procurement tender process, could exert downward pressure on product demand and pricing.

⚠️ Supply Chain and Manufacturing Resilience: The transcript highlights risks related to disruptions in global transportation networks, the ability to consistently source raw materials and components, and potential interruptions in manufacturing or sterilization processes. These factors, including any restrictions on the use of ethylene oxide for sterilization, could impact production capacity, increase costs, and delay product availability, thereby affecting revenue and profitability.

🔮 CEO / Management Guidance

BD updated its full-year fiscal 2026 guidance, now expecting revenue growth toward the high end of its previously stated low single-digit range. The company also raised the midpoint of its adjusted diluted EPS guidance, projecting it to be between $12.62 and $12.72 for the full fiscal year, up from the prior range of $12.52 to $12.72. This reflects management's increased confidence in ongoing momentum and disciplined execution across its focused MedTech platforms.

💬 Key Quote

We delivered a strong third quarter, with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations. Our first full quarter as New BD demonstrates the early benefits of a more focused MedTech company, with strong momentum across our key growth platforms, continued innovation and further progress through BD Excellence. — Tom Polen, chairman, CEO and president of BD

📅 Quarter-over-Quarter Comparison

Comparing Q3 FY2026 vs Q2 FY2026 All quarters →

Revenue $4.7B → $5.0B

EPS $12.52 → $12.62

Sentiment 🟢 Bullish → 🟢 Bullish

🏢 About Becton Dickinson & Co.

Becton Dickinson & Co. (BDX) is a publicly listed company on the NYSE exchange in the Healthcare sector. EarningsBloom tracks its quarterly earnings calls to provide free AI-generated summaries for investors.

BDX NYSE Healthcare All Becton Dickinson & Co. Summaries →

📈 Want to act on this insight?

🇮🇳 Open Zerodha Account 🌱 Start with Groww 📄 Full Transcript on Seeking Alpha 📚 Learn Financial Analysis

Topics: Financial Performance Strategic Growth Product Innovation Guidance Update

📁 More from Becton Dickinson & Co.

View all earnings summaries for Becton Dickinson & Co. →